US 12,123,005 B2
Fusion proteins and methods thereof
Antonio Iavarone, New York, NY (US); Anna Lasorella, New York, NY (US); and Raul Rabadan, New York, NY (US)
Assigned to THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, New York, NY (US)
Filed by The Trustees of Columbia University in the City of New York, New York, NY (US)
Filed on Jul. 10, 2019, as Appl. No. 16/508,021.
Application 16/508,021 is a division of application No. 14/604,530, filed on Jan. 23, 2015, abandoned.
Application 14/604,530 is a continuation in part of application No. PCT/US2013/051888, filed on Jul. 24, 2013.
Claims priority of provisional application 62/096,311, filed on Dec. 23, 2014.
Claims priority of provisional application 61/675,006, filed on Jul. 24, 2012.
Prior Publication US 2020/0174003 A1, Jun. 4, 2020
Int. Cl. C12Q 1/6886 (2018.01); C07K 14/47 (2006.01); C07K 14/71 (2006.01); C07K 14/82 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C12N 9/12 (2006.01); C12N 15/62 (2006.01); G01N 33/574 (2006.01)
CPC C12N 15/62 (2013.01) [C07K 14/47 (2013.01); C07K 14/71 (2013.01); C07K 14/82 (2013.01); C07K 16/18 (2013.01); C07K 16/2863 (2013.01); C12N 9/12 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57492 (2013.01); C07K 2319/00 (2013.01); C07K 2319/73 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/91205 (2013.01)] 17 Claims
 
1. A method for treating a FGFR3-TACC3 fusion associated cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of NVP-BGJ398, wherein the subject has a FGFR3-TACC3 fusion associated cancer, wherein the FGFR3-TACC3 fusion comprises a tyrosine kinase domain of FGFR3 fused to the TACC domain of transforming acidic coiled-coil-containing (TACC)-3.